ursofalk

PreclinicalSmall molecule

AAlexandra Hospital, Athens, Greece

ursofalk is one of 4 small molecule programs targeting Intrahepatic Cholestasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholestasisActive, not recruiting

Intrahepatic CholestasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Intrahepatic Cholestasis

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Livmarli

MMirum Pharmaceuticals, Inc.

Phase 3

5 3

Bylvay

Ipsen

Preclinical

1 4

ursofalk

AAlexandra Hospital, Athens, Greece

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intrahepatic Cholestasis1 trial

Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives

Unknown status·—··NCT04281082·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ursofalk. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ursofalk compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ursofalk. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alexandra Hospital, Athens, Greece company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlexandra Hospital, Athens, Greece

ursofalk

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intrahepatic Cholestasis1 trial

References

Drug Info

Quick Facts

Related News